Patents by Inventor Alfredo C. Castro

Alfredo C. Castro has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230148061
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: August 2, 2022
    Publication date: May 11, 2023
    Inventor: Alfredo C. CASTRO
  • Patent number: 11608329
    Abstract: The present invention provides AHR agonists, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: December 18, 2020
    Date of Patent: March 21, 2023
    Assignee: IKENA ONCOLOGY, INC.
    Inventors: Alfredo C. Castro, Karen J. McGovern, Michael Burke
  • Patent number: 11607404
    Abstract: This application is directed to inhibitors of RAD51 represented by the following structural formula: in combination with a PARP inhibitor, and methods for their use, such as to treat cancer, autoimmune diseases, immune deficiencies, or neurodegenerative diseases.
    Type: Grant
    Filed: March 25, 2020
    Date of Patent: March 21, 2023
    Assignee: Cyteir Therapeutics, Inc.
    Inventors: Alfredo C. Castro, Melinda Day, Tyler Maclay, Casey Cameron McComas, Kevin Mills, Joseph Vacca
  • Patent number: 11602527
    Abstract: The invention provides methods for treating various conditions using derivatives of cyclopamine having the following formula:
    Type: Grant
    Filed: September 28, 2020
    Date of Patent: March 14, 2023
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Alfredo C. Castro, Michael J. Grogan, Karen J. McGovern, Martin R. Tremblay
  • Patent number: 11591339
    Abstract: The present invention provides solid forms of (R)—N-(2-(5-fluoropyridin-3-yl)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-4-yl)-2,3,4,9-tetrahydro-1H-carbazol-3-amine maleate (Compound 2) represented by the formula:
    Type: Grant
    Filed: November 25, 2020
    Date of Patent: February 28, 2023
    Assignee: IKENA ONCOLOGY, INC.
    Inventors: Alfredo C. Castro, James Martin Nolan, III, Sarah Jean Bethune, Corinne Marie Folberth
  • Publication number: 20230028336
    Abstract: The present invention provides compounds useful as inhibitors of AHR, compositions thereof, and methods of using the same.
    Type: Application
    Filed: May 6, 2022
    Publication date: January 26, 2023
    Inventors: Alfredo C. CASTRO, Catherine A. EVANS
  • Publication number: 20230026232
    Abstract: The present invention provides AHR inhibitors, formulations and unit dosage forms thereof, and methods of use thereof.
    Type: Application
    Filed: November 25, 2020
    Publication date: January 26, 2023
    Inventors: Alfredo C. Castro, James Martin NOLAN, III, Xiaoyan Michelle ZHANG, Jason SAGER
  • Patent number: 11555026
    Abstract: The present invention provides compounds useful as inhibitors of AHR, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: June 2, 2020
    Date of Patent: January 17, 2023
    Assignee: IKENA ONCOLOGY, INC.
    Inventors: Alfredo C. Castro, Catherine Anne Evans
  • Patent number: 11541059
    Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.
    Type: Grant
    Filed: March 11, 2020
    Date of Patent: January 3, 2023
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Jeffery L. Kutok, David G. Winkler, Vito J. Palombella, Alfredo C. Castro, Catherine A. Evans, Somarajannair Janardanannair, Andre Lescarbeau, Tao Liu, Martin R. Tremblay
  • Publication number: 20220372038
    Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.
    Type: Application
    Filed: March 15, 2021
    Publication date: November 24, 2022
    Inventors: Alfredo C. Castro, Catherine A. Evans, Somarajannair Janardanannair, Andre Lescarbeau, Tao Liu, Martin R. Tremblay
  • Patent number: 11458149
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: May 29, 2020
    Date of Patent: October 4, 2022
    Assignee: IKENA ONCOLOGY, INC.
    Inventor: Alfredo C. Castro
  • Publication number: 20220251048
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: January 3, 2022
    Publication date: August 11, 2022
    Inventor: Alfredo C. CASTRO
  • Patent number: 11358969
    Abstract: The present invention provides compounds useful as inhibitors of AHR, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: April 8, 2020
    Date of Patent: June 14, 2022
    Assignee: IKENA ONCOLOGY, INC.
    Inventors: Alfredo C. Castro, Catherine A. Evans
  • Publication number: 20220144839
    Abstract: The present invention provides compounds useful as inhibitors of AHR, compositions thereof, and methods of using the same.
    Type: Application
    Filed: October 16, 2019
    Publication date: May 12, 2022
    Inventor: Alfredo C. CASTRO
  • Patent number: 11291655
    Abstract: This application is directed to inhibitors of RAD51, and methods for their use, such as to treat or prevent conditions involving mitochondrial defects.
    Type: Grant
    Filed: July 11, 2018
    Date of Patent: April 5, 2022
    Assignee: Cyteir Therapeutics, Inc.
    Inventors: Alfredo C. Castro, Casey Cameron McComas, Joseph Vacca
  • Patent number: 11274082
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: May 29, 2020
    Date of Patent: March 15, 2022
    Assignee: IKENA ONCOLOGY, INC.
    Inventor: Alfredo C. Castro
  • Publication number: 20220056022
    Abstract: This application is directed to inhibitors of RAD51 represented by the following structural formula, and methods for their use, such as to treat cancer, autoimmune diseases, immune deficiencies, or neurodegenerative diseases.
    Type: Application
    Filed: June 30, 2021
    Publication date: February 24, 2022
    Inventors: Alfredo C. CASTRO, Casey Cameron MCCOMAS, Joseph VACCA, Tyler MACLAY
  • Publication number: 20210315909
    Abstract: The present invention provides co-crystal and salt forms, and compositions and methods thereof, useful for treating various diseases, disorders or conditions in which EP4 prostaglandin receptors are implicated in the mediation of a proliferative disorder, by the administration of small molecule therapeutics acting as inhibitors of prostaglandin EP4 receptor activity.
    Type: Application
    Filed: July 11, 2019
    Publication date: October 14, 2021
    Inventors: Alfredo C. CASTRO, David T. JONAITIS
  • Publication number: 20210300912
    Abstract: The present invention provides AHR agonists, compositions thereof, and methods of using the same.
    Type: Application
    Filed: December 18, 2020
    Publication date: September 30, 2021
    Inventors: Alfredo C. Castro, Karen J. McGovern, Michael Burke
  • Publication number: 20210300921
    Abstract: The present invention provides N-((4-(2-ethyl-4,6-dimethyl-1H-imidazo[4,5-c]pyridin-1-yl)phenethyl)carbamoyl)-4-methylbenzenesulfonamide compositions, and the use thereof for treating a proliferative disorder.
    Type: Application
    Filed: July 11, 2019
    Publication date: September 30, 2021
    Inventors: Mark MANFREDI, Jeffrey ECSEDY, Alfredo C. CASTRO, Yoshiyuki OKUMURA